TSI - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Real-Time Viable Particle Counters, like TSI’s BioTrak™ Products, are a new Rapid Microbial Methods (RMM) technique, which has recently been released to the market. These new products are based on the measurement technique of Laser-Induced Fluorescence (LIF). With LIF, essentially, when biological particles are excited by a specific wavelength of light, the emit light at a different, known wavelength. While most LIF based products use similar measurements, there are some considerable differences in products offered on the market.

The BioTrak Real-Time Viable Particle Counter is the only product that measures non-viable particles, just like Portable Particle Counters, and is capable of classifying a cleanroom. This establishes that room meets the specified airborne particulate cleanliness standard, matching previous measurements. The BioTrak Particle Counter also comes with excellent discrimination performance. Some of the early products on the market have had issues with determining viable from non-viable particles. This produces too many “false positives”, and provides uncertainty with customers that the measurement works. To address this issue, TSI has conducted extensive testing and developed algorithms that are proven to provide a much better level of discrimination.

Further, through an evaluation program, you should be able to test the BioTrak against typical sample plates and use that information to properly assess future measurements. Finally, the BioTrak Real-Time Viable Particle Counter comes with a unique built-in sample collection filter that can collect the same particles that were measured. Those samples can then be sent to a lab for more detailed evaluation.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here